Research Articles - Macular Degeneration
Drs. Albert Maguire, Katherine High and Jean Bennett of CHOP have successfully reversed blindness in twelve LCA patients.
CHOP researchers began the study two years ago and, in 2008, reported vision improvement for their first three participants, all of whom were young adults. The results of these first participants were heralded worldwide as one
Researchers around the world are calling it a scientific breakthrough; a medical milestone. Corey’s parents, Ethan and Nancy, call it a dream come true.
Ethan, Nancy and Corey Haas
attend a press conference at
The Children’s Hospital of Philadelphia
Just 13 months ago Corey was almost completely blind. With poor visual acuity, little color perception and a very limited visual field, he was challenged in
A recent research paper in The Journal of the American Medical Association reports that regular aspirin use may slightly increase the risk of advanced age-related macular degeneration (AMD). But many experts, including the paper’s authors, say that people with AMD should not stop taking aspirin for treatment of cardiovascular disease or as prescribed by a doctor for other health issues.
Studies of AMD and aspirin have been prompted by the concern that aspirin might
The RIKEN Institute in Japan has started a clinical study for a wet age-related macular degeneration (AMD) treatment derived from induced pluripotent stem cells (iPSC) — mature cells that have been genetically reprogrammed to a stem cell-like state. The therapy involves replacement of a layer of cells known as
In the first-ever clinical trials of a stem cell treatment for retinal disease, two women – one with dry age-related macular degeneration (AMD), the other with Stargardt disease – demonstrated improved vision, including the ability to read more lines on an eye chart with their treated eyes.
Most important, the treatment is improving their independence and ability to perform daily activities. The 78-year-old woman with dry AMD says that she has begun making her own breakfast and shopping by herself. The Stargardt patient,
A clinical trial for a human neural stem-cell therapy for people with dry age-related macular degeneration (AMD) has shown encouraging interim results. The rate of geographic atrophy — the loss of photoreceptors and supportive cells known as retinal pigment epithelium — was reduced by 70 percent in treated eyes versus
A new treatment for the wet form of age-related macular degeneration (AMD) has the potential to last up to three times longer than current treatments, according to the results of a pre-clinical study published, online, in the journal Biomaterials. Developed by researchers at Johns Hopkins Medical Center, the new drug and its delivery system were successfully tested in mice. While a
- Results from a clinical trial known as the Age-Related Eye Disease Study 2 (AREDS2), conducted by the National Eye Institute (NEI), have led researchers to recommend updating the formula for reducing risk of advanced age-related macular degeneration (AMD). The first AREDS called for using beta carotene, but now researchers believe that lutein and zeaxanthin appear to be more effective in reducing risk of the disease. In addition, beta carotene was linked to higher rates of lung cancer for current and former
Therapy that promotes independence and social activity may help prevent depression in people with low vision caused by age-related macular degeneration (AMD), which affects more than 10 million people in the United States. Known as behavior activation, the therapeutic approach reduced depression by nearly 50 percent in a clinical study of 188 people who averaged 84 years of age. Results from the research